Oyster Point Pharma submitted a new drug application to the FDA for its nasal spray to treat signs and symptoms of dry eye disease, according to a press release.
OC-01 (varenicline) binds to the trigeminal nerve when administered in the nasal cavity. The binding triggers the parasympathetic nervous system, initiating the production of all three layers of tear film, Jeffrey Nau, PhD, MMS, president and CEO of Oyster Point, told Healio/OSN.
“It works fairly immediately, so the patient can basically treat themselves with their own natural tear film,” Nau said.
(Read more...)
Uncategorized